Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02489305 · ClinicalTrials.gov registry record
Study to Evaluate Potential Predictors of Relapse in Participants With Major Depressive Disorder (MDD)
A clinical trial of Depressive Disorder, Major, sponsored by Janssen Research & Development.
- Completed
- Registry status
- 330
- Enrollment target
- 20
- Study locations
NCT02489305: Completed study of Depressive Disorder, Major, sponsored by Janssen Research & Development.
NCT02489305 is a study of Depressive Disorder, Major that has completed, run by Janssen Research & Development. The registered enrollment target is 330 participants, above the 236-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (40% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02489305, a study of Depressive Disorder, Major, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- 330 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to identify if there are self-reported or objective measures related to mood parameters that can predict near-term relapse (within 1 month or at another identified time point before meeting the criteria for relapse) or early symptomatic changes indicative of relapse prodrome in major depressive disorder (MDD).
Primary Outcome
Relapse will be defined as any of the following: a) MADRS total score greater than or equal to 22 on at least two consecutive visits, with an interval of 1-2 weeks; b) Hospitalization for worsening of depression; c) Suicidal ideation with intent, or suicidal behavior and d) Other (investigator will be asked to describe). MADRS total score ranges from 0 to 60, Higher scores represents a more severe condition.
Conditions Studied
Study Locations (20)
California
- - Glendale
- - Oceanside
- - San Diego
- - Sherman Oaks
- - Stanford
Florida
- - Jacksonville
- - Orlando
- - Tampa
Illinois
- - Chicago
- - Skokie
- - Springfield
Alabama
- - Birmingham
Connecticut
- - Hartford
Georgia
- - Augusta
Iowa
- - Iowa City
Kansas
- - Wichita
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2014-12-15 |
| Est. Completion | 2018-05-01 |
What the finished NCT02489305 record still lists
NCT02489305 is an observational study that tracks outcomes without assigning an intervention. The registered 330 participants enrollment target is mid-sized for trials with a published cap, above the 236-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (40% higher).
The record links to 1 condition, with Depressive Disorder, Major appearing as the primary indexed condition, and to 0 interventions.
NCT02489305 names 20 study sites across 12 states, led by California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT02489305 about?
NCT02489305 is a clinical study titled "Study to Evaluate Potential Predictors of Relapse in Participants With Major Depressive Disorder (MDD)". The purpose of this study is to identify if there are self-reported or objective measures related to mood parameters that can predict near-term relapse (within 1 month or at another identified time point before meeting the criteria for relapse) or early symptomatic changes indicative of relapse prod...
What is the current status of trial NCT02489305?
This trial is currently completed. The enrollment target is 330 participants. The study started on 2014-12-15. Estimated completion is 2018-05-01.
What conditions does trial NCT02489305 study?
This clinical trial studies the following conditions: Depressive Disorder, Major.
Who is sponsoring clinical trial NCT02489305?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02489305 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depressive Disorder, Major
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02489305's enrollment target sits among peer trials
330 14th of 52 higher than 39 of 52 other Depressive Disorder, Major trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depressive Disorder, Major trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dosing rTMS for Depression Post-SCI
RECRUITING · NA
-
A Study to Evaluate Sleep Electroencephalogram (EEG) Features (Brain Activity While Sleeping) in Participants With Major Depressive Disorder (MDD)
RECRUITING
-
Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab
RECRUITING · Phase 2
-
InMotion - Telehealth Delivered Exercise Promotion to Treat Major Depression After TBI
RECRUITING · NA
-
Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia
RECRUITING · NA
-
Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00359684 · 330 participants
Use of Cysteamine in the Treatment of Cystinosis
- NCT03817502 · 330 participants · Phase 3
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
- NCT03922724 · 330 participants · Phase 2
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
- NCT03932773 · 330 participants · NA
Multi-site Confirmatory Efficacy Treatment Trial of Combat-related PTSD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI